Home › Funds › Athos Capital Ltd › RNA

Athos Capital Ltd position in RNA

ATRIUM THERAPEUTICS INC · Health Care

Athos Capital Ltd reported holding 107,965 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$894K, representing 0.51% of its reported portfolio and ranking #20 among its reported holdings. Athos Capital Ltd has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)107.97K sh
Reported value held$894.00K
Portfolio Weight0.51%
First reportedQ1 2026
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Athos Capital Ltd's RNA position evolved

Athos Capital Ltd first disclosed a stake in RNA in Q1 2026 at 107,965 shares (US$1.4M). The position peaked in Q2 2026 at 107,965 shares, worth US$1.5M. Across 3 filings, Athos Capital Ltd held the position steady without any share-count change. The most recent filing (Q3 2026) shows 107,965 shares valued at US$894K.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 107.97K $1.44M New
Q2 2026 107.97K $1.45M Hold
Q3 2026 107.97K $894.00K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RNA and 13F data

RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 98 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), TIG Advisors, LLC (US$7.6M), Slotnik Capital, LLC (US$3.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RNA

All RNA fund holders →

FAQ

How long has Athos Capital Ltd held RNA?

Athos Capital Ltd has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Athos Capital Ltd's current position in RNA?

As of Q3 2026, Athos Capital Ltd holds 107.97K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $894.00K, representing 0.51% of its reported portfolio and ranking #20.

Has Athos Capital Ltd been buying or selling RNA?

In the latest 13F filing (Q3 2026), Athos Capital Ltd held unchanged its position in RNA. The position peaked in Q2 2026 at 107.97K shares.

Which other funds hold RNA?

Other major institutional holders of RNA include Sessa Capital IM, L.P., TIG Advisors, LLC, Slotnik Capital, LLC, among 98 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.